Trung Huynh
Stock Analyst at UBS
(4.65)
# 202
Out of 4,989 analysts
52
Total ratings
65.71%
Success rate
24.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $2.50 | +900.00% | 3 | Aug 15, 2025 | |
| INSM Insmed | Maintains: Buy | $133 → $140 | $144.76 | -3.29% | 7 | Aug 13, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,050 → $895 | $751.99 | +19.02% | 9 | Aug 8, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $285.41 | +11.07% | 6 | Aug 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $560 → $584 | $591.99 | -1.35% | 4 | Jul 11, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $24.61 | +54.41% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $24.03 | +4.04% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $45.02 | +19.95% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.19 | +219.63% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $5.80 | +124.14% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $176.19 | -0.68% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $81.51 | +54.58% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $222.47 | -23.59% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.74 | - | 1 | Mar 23, 2021 |
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $2.50
Upside: +900.00%
Insmed
Aug 13, 2025
Maintains: Buy
Price Target: $133 → $140
Current: $144.76
Upside: -3.29%
Eli Lilly and Company
Aug 8, 2025
Maintains: Buy
Price Target: $1,050 → $895
Current: $751.99
Upside: +19.02%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $285.41
Upside: +11.07%
Regeneron Pharmaceuticals
Jul 11, 2025
Maintains: Neutral
Price Target: $560 → $584
Current: $591.99
Upside: -1.35%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $24.61
Upside: +54.41%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $24.03
Upside: +4.04%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $45.02
Upside: +19.95%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.19
Upside: +219.63%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $5.80
Upside: +124.14%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $176.19
Upside: -0.68%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $81.51
Upside: +54.58%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $222.47
Upside: -23.59%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.74
Upside: -